Action of a thymic cytokine TsIF in reversing the autoimmune disease state of the MRL/1pr mouse.
T suppressor cells differentiate from bone marrow precursors when cocultured with thymic epithelium, a thymic-derived cytokine TsIF, or mixture of both. (TsIF is a trademark of Ventrex Laboratories, Inc., Portland, ME, and is the subject of a U.S. patent by Ventrex Laboratories, Inc., Portland, ME.) These cells, when transplanted into the lupus-rheumatoid arthritis-prone mouse, prevent acquisition of disease as assessed by lack of both antinuclear antibody, rheumatoid factor, and survival beyond mean time for MRL/lpr mice. When TsIF is administered directly into these lupus-rheumatoid arthritis-prone mice, an equivalent sparing effect is manifested.
Miller
H C
HC
Biotherapeutics, Franklin, TN 37064.
Vito
C
C
D000818:Animals; D000974:Antibodies, Antinuclear / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001685:Biological Factors / Q000627:therapeutic use*; D001853:Bone Marrow / Q000276:immunology; D002478:Cells, Cultured; D016207:Cytokines; D004848:Epithelium / Q000276:immunology; D005260:Female; D005819:Genetic Markers; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D012217:Rheumatoid Factor / Q000502:physiology; D013491:Suppressor Factors, Immunologic / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D013950:Thymus Gland / Q000276:immunology
D000974:Antibodies, Antinuclear; D001685:Biological Factors; D016207:Cytokines; D005819:Genetic Markers; D013491:Suppressor Factors, Immunologic; D012217:Rheumatoid Factor